143 related articles for article (PubMed ID: 31837125)
1. Update: Pediatric Diabetes.
Gujral J; Sethuram S; Rapaport R
J Diabetes; 2020 Mar; 12(3):262-264. PubMed ID: 31837125
[No Abstract] [Full Text] [Related]
2. The efficacy and safety of exenatide once weekly in patients with type 2 diabetes.
Heimbürger SM; Brønden A; Johansen NJ; Dejgaard TF; Vilsbøll T; Knop FK
Expert Opin Pharmacother; 2019 Apr; 20(5):501-510. PubMed ID: 30730773
[TBL] [Abstract][Full Text] [Related]
3. Editorial: Do Some Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) Reduce Macrovascular Complications of Type 2 Diabetes Mellitus A Commentary on the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) Trial.
Athyros VG; Katsiki N; Tentolouris N
Curr Vasc Pharmacol; 2016; 14(5):469-473. PubMed ID: 27633290
[No Abstract] [Full Text] [Related]
4. Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes.
Nauck MA; Kahle M; Baranov O; Deacon CF; Holst JJ
Diabetes Obes Metab; 2017 Feb; 19(2):200-207. PubMed ID: 27709794
[TBL] [Abstract][Full Text] [Related]
5. Glycemic Control and Weight Outcomes for Exenatide Once Weekly Versus Liraglutide in Patients with Type 2 Diabetes: A 1-Year Retrospective Cohort Analysis.
McAdam-Marx C; Nguyen H; Schauerhamer MB; Singhal M; Unni S; Ye X; Cobden D
Clin Ther; 2016 Dec; 38(12):2642-2651. PubMed ID: 27889301
[TBL] [Abstract][Full Text] [Related]
6. FDA approval of GLP-1 receptor agonist (liraglutide) for use in children.
Bacha F
Lancet Child Adolesc Health; 2019 Sep; 3(9):595-597. PubMed ID: 31345736
[No Abstract] [Full Text] [Related]
7. Fixed-ratio combination therapy with GLP-1 receptor agonist liraglutide and insulin degludec in people with type 2 diabetes.
Østergaard L; Frandsen CS; Dejgaard TF; Madsbad S
Expert Rev Clin Pharmacol; 2017 Jun; 10(6):621-632. PubMed ID: 28349716
[TBL] [Abstract][Full Text] [Related]
8. Effect of Liraglutide on Arterial Inflammation Assessed as [
Ripa RS; Zobel EH; von Scholten BJ; Jensen JK; Binderup T; Diaz LJ; Curovic VR; Hansen TW; Rossing P; Kjaer A
Circ Cardiovasc Imaging; 2021 Jul; 14(7):e012174. PubMed ID: 34187185
[TBL] [Abstract][Full Text] [Related]
9. Real-world effectiveness of liraglutide versus dulaglutide in Japanese patients with type 2 diabetes: a retrospective study.
Tanaka K; Okada Y; Tokutsu A; Tanaka Y
Sci Rep; 2022 Jan; 12(1):154. PubMed ID: 34997102
[TBL] [Abstract][Full Text] [Related]
10. Liraglutide vs. lixisenatide in obese type 2 diabetes mellitus patients: What effect should we expect in routine clinical practice?
Moreno-Fernandez J; Garcia-Seco JA; Seco Segura AM; Garcia-Seco F; Rozas Moreno PJ; Aguirre Sanchez-Covisa M
Prim Care Diabetes; 2020 Feb; 14(1):68-74. PubMed ID: 31171461
[TBL] [Abstract][Full Text] [Related]
11. Does Neprilysin Inhibition Potentiate or Minimize the Adverse Effects of Glucagon-Like Peptide-1 Receptor Agonists in Chronic Heart Failure?
Packer M
J Card Fail; 2018 Feb; 24(2):109-111. PubMed ID: 29305970
[No Abstract] [Full Text] [Related]
12. Long-term Cost-effectiveness of Two GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus in the Italian Setting: Liraglutide Versus Lixisenatide.
Hunt B; Kragh N; McConnachie CC; Valentine WJ; Rossi MC; Montagnoli R
Clin Ther; 2017 Jul; 39(7):1347-1359. PubMed ID: 28625506
[TBL] [Abstract][Full Text] [Related]
13. [Not Available].
Fischli S; Henzen C
Ther Umsch; 2017; 74(8):433-439. PubMed ID: 29461151
[No Abstract] [Full Text] [Related]
14. Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients.
Smits MM; Tonneijck L; Muskiet MH; Hoekstra T; Kramer MH; Diamant M; Nieuwdorp M; Groen AK; Cahen DL; van Raalte DH
Diabetes Obes Metab; 2016 Dec; 18(12):1217-1225. PubMed ID: 27451030
[TBL] [Abstract][Full Text] [Related]
15. Glucagon-like peptide-1 receptor agonists and cardiovascular disease: from LEADER to EXSCEL.
Torekov SS
Cardiovasc Res; 2018 Aug; 114(10):e70-e71. PubMed ID: 30052921
[No Abstract] [Full Text] [Related]
16. Long-term efficacy and safety of combined insulin and glucagon-like peptide-1 therapy: Evidence from the LEADER trial.
Tack CJ; Jacob S; Desouza C; Bain SC; Buse JB; Nauck MA; Petrie JR; Poulter NR; Pratley RE; Stegmann HVBK; Bosch-Traberg H; Startseva E; Zinman B;
Diabetes Obes Metab; 2019 Nov; 21(11):2450-2458. PubMed ID: 31282028
[TBL] [Abstract][Full Text] [Related]
17. Weight Outcomes With Empagliflozin as Compared With Liraglutide in Veterans With Type 2 Diabetes Mellitus.
Grabarczyk TR; Wissman NK
Ann Pharmacother; 2020 Oct; 54(10):981-987. PubMed ID: 32274930
[TBL] [Abstract][Full Text] [Related]
18. MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?
Nauck MA; Meier JJ
Eur J Endocrinol; 2019 Dec; 181(6):R211-R234. PubMed ID: 31600725
[TBL] [Abstract][Full Text] [Related]
19. Long-acting GLP-1RAs: An overview of efficacy, safety, and their role in type 2 diabetes management.
Chun JH; Butts A
JAAPA; 2020 Aug; 33(S8 Suppl 1):3-18. PubMed ID: 32756220
[TBL] [Abstract][Full Text] [Related]
20. Drug Combo Adds No Benefit in Patients with Type 2 Diabetes.
Geurin MD
Am Fam Physician; 2016 Mar; 93(6):436-8. PubMed ID: 26977827
[No Abstract] [Full Text] [Related]
[Next] [New Search]
